About this trial
Juvenile idiopathic arthritis (JIA) is a rare chronic inflammatory rheumatic disease that begins during childhood and may persist into adulthood in many patients. In addition to joint pain, swelling, and long-term articular damage, chronic inflammatory diseases may also be associated with early sarcopenia, defined as a loss of muscle strength and muscle mass. While this association has been described in adult inflammatory rheumatic diseases, it has not been well studied in patients with JIA.
The aim of this study is to screen for sarcopenia in adolescents and adults with JIA in France. Sarcopenia will be assessed using validated questionnaires, hand grip strength measured with a Jamar dynamometer, and body composition measured by dual-energy X-ray absorptiometry (DEXA). Completion of validated questionnaires will assess nutritional status, fatigue, physical activity, and functional impact. Socio-demographic and clinical data will also be collected from medical records.
This multicenter cross-sectional study will be conducted between June 2026 and October 2027 in 11 French hospitals. Eligible participants are patients aged 15 to 40 years with JIA diagnosed according to ILAR criteria and followed in a French hospital.
This study will provide the first estimate of sarcopenia prevalence among patients with JIA in France. It will also help identify factors associated with sarcopenia and its impact on daily functioning and quality of life. In the longer term, the findings may help clinicians better identify patients at risk and support earlier management focused on disease control, physical activity, and nutritional care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients followed in French hospitals participating in the study for juvenile idiopathic arthritis, all forms combined, diagnosed according to the ILAR criteria defined in Edmonton in 2001
Patients aged 15 to 40 years
Affiliated to social security
Agreeing to participate in the study and having given their written consent (signed consent form).
Disqualifiers
Patient under legal guardianship
Patient not covered by social security
Pregnant woman
Inability to perform a functional test required by the study (grip test or whole-body DEXA scan)
Trial design
Single group
Treatments tested in this trial
Sarcopenia screening assessment
Other interventionParticipants will undergo a standardized single-visit assessment including hand grip strength measurement, whole-body DEXA scan for body composition, validated questionnaires, and collection of socio-demographic and clinical data from medical records.
Treatment groups
Trial outcomes
Primary outcomes
Sarcopenia
A cross-sectional assessment of sarcopenia for each included patient will be performed at a participating hospital center: Performance of a hand grip test using a hand dynamometer (3 consecutive measurements on the dominant hand) and a whole-body DEXA scan with measurement of the appendiceal mass index Confirmation by the best grip test value \< -2 SD according to the patient's age and sex on the reference curves associated with a pathological whole-body DEXA (appendiceal mass index ≤ 7 kg/m2 for men, ≤ 5.5 kg/m2 for women)
Secondary outcomes
Fatigue assessed by FACIT-F
Fatigue assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire
Physical activity assessed by IPAQ
Physical activity assessed using the International Physical Activity Questionnaire (IPAQ)
Functional disability assessed by HAQ-DI
Functional disability assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI).
Health-related quality of life assessed by SF-12
Health-related quality of life assessed using the 12-Item Short Form Health Survey (SF-12).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: